



# Artificial intelligence applied to image-guided radiation therapy (IGRT): a systematic review by the Young Group of the Italian Association of Radiotherapy and Clinical Oncology (yAIRO)

Luca Boldrini<sup>1,2</sup> · Andrea D'Aviero<sup>3</sup> · Francesca De Felice<sup>4,5</sup> · Isacco Desideri<sup>6</sup> · Roberta Grassi<sup>7</sup> · Carlo Greco<sup>8</sup> · Giuseppe Carlo Iorio<sup>9</sup> · Valerio Nardone<sup>7</sup> · Antonio Piras<sup>10</sup> · Viola Salvestrini<sup>6,11</sup>

Received: 5 April 2023 / Accepted: 16 August 2023

© Italian Society of Medical Radiology 2023

## Abstract

**Introduction** The advent of image-guided radiation therapy (IGRT) has recently changed the workflow of radiation treatments by ensuring highly collimated treatments. Artificial intelligence (AI) and radiomics are tools that have shown promising results for diagnosis, treatment optimization and outcome prediction. This review aims to assess the impact of AI and radiomics on modern IGRT modalities in RT.

**Methods** A PubMed/MEDLINE and Embase systematic review was conducted to investigate the impact of radiomics and AI to modern IGRT modalities. The search strategy was “Radiomics” AND “Cone Beam Computed Tomography”; “Radiomics” AND “Magnetic Resonance guided Radiotherapy”; “Radiomics” AND “on board Magnetic Resonance Radiotherapy”; “Artificial Intelligence” AND “Cone Beam Computed Tomography”; “Artificial Intelligence” AND “Magnetic Resonance guided Radiotherapy”; “Artificial Intelligence” AND “on board Magnetic Resonance Radiotherapy” and only original articles up to 01.11.2022 were considered.

**Results** A total of 402 studies were obtained using the previously mentioned search strategy on PubMed and Embase. The analysis was performed on a total of 84 papers obtained following the complete selection process. Radiomics application to IGRT was analyzed in 23 papers, while a total 61 papers were focused on the impact of AI on IGRT techniques.

**Discussion** AI and radiomics seem to significantly impact IGRT in all the phases of RT workflow, even if the evidence in the literature is based on retrospective data. Further studies are needed to confirm these tools' potential and provide a stronger correlation with clinical outcomes and gold-standard treatment strategies.

**Keywords** Artificial intelligence · Radiomics · Deep learning · Machine learning · Image-guided radiation therapy

Antonio Piras  
antoniopiras88@gmail.com

<sup>1</sup> UOC Radioterapia Oncologica, Fondazione Policlinico Universitario IRCCS “A. Gemelli”, Rome, Italy

<sup>2</sup> Università Cattolica del Sacro Cuore, Rome, Italy

<sup>3</sup> Radiation Oncology, Mater Olbia Hospital, Olbia, Sassari, Italy

<sup>4</sup> Radiation Oncology, Department of Radiological, Policlinico Umberto I, Rome, Italy

<sup>5</sup> Oncological and Pathological Sciences, “Sapienza” University of Rome, Rome, Italy

<sup>6</sup> Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy

<sup>7</sup> Department of Precision Medicine, University of Campania “L. Vanvitelli”, Naples, Italy

<sup>8</sup> Department of Radiation Oncology, Università Campus Bio-Medico di Roma, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy

<sup>9</sup> Department of Oncology, Radiation Oncology, University of Turin, Turin, Italy

<sup>10</sup> UO Radioterapia Oncologica, Villa Santa Teresa, Bagheria, Palermo, Italy

<sup>11</sup> Cyberknife Center, Istituto Fiorentino di Cura e Assistenza (IFCA), 50139 Florence, Italy

## Introduction

Artificial intelligence (AI) is a field of computer science capable of analyzing complex datasets and exploring meaningful relationships within different data formats. It has been applied in numerous health care settings, such as diagnosis, treatment optimization and outcome prediction [1].

AI is based on a wide collection of algorithms to perform tasks correlated with human thinking or intelligence through the appliance of machine learning (ML) and deep learning (DL) as subdomains [2].

The applications of AI in radiotherapy (RT) are numerous and aim to improve the accuracy, precision, efficiency and overall quality of the treatment of cancer patients [3, 4].

Automated segmentation, automated planning, synthetic image generation and automated quality assurance represent only some of the applications of AI in RT, opening new frontiers in several steps of the RT workflow [5–7].

AI has been successfully applied also to image sciences. As an example, radiomics can provide quantitative features from medical images that can be correlated with various biological characteristics and clinical endpoints [8]. Its use in the field of radiation oncology has offered new important insights for treatment optimization [8–12].

Radiomics allows researchers to predict different outcomes (i.e., response to treatment or treatment-induced toxicities) and can be applied also to RT treatment-related images, besides the traditional applications to standard diagnostic images [13–16].

Image-guided Radiation Therapy (IGRT) has become increasingly important in recent years, allowing to overcome numerous pitfalls of past RT. Indeed, IGRT is crucial in highly conformal treatments made possible by the recent volumetric techniques such as intensity-modulated Radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT) [17, 18].

IGRT allows to verify the correct position of the target and the inter-fraction and intra-fraction variability of the therapy volumes, reducing the risk of target missing and unnecessary irradiation of organs at risk (OAR) that may cause potentially severe treatment-related toxicity, especially in high-dose single fraction treatments such as stereotactic body RT (SBRT) [19, 20].

The recent introduction of Magnetic Resonance imaging-guided radiotherapy (MRIgRT) has brought further innovations, thanks to the new application of AI techniques, such as the possibility to perform active direct gating on movable targets and online treatment adaptation [21].

AI can facilitate and speed up these processes, especially in online adaptive radiotherapy treatments (ART) [22–24].

These new techniques are supporting the introduction of innovative treatment regimens that may obtain more effective and safe treatments for cancer patients [25–29].

This will pave the way towards more hypofractionated regimens, escalating treatment doses, and reducing hospital access and relative logistic burden, as recently observed also during the Covid19 pandemic [30].

The aim of this systematic review is to assess the status and future perspectives of the use of AI and Radiomics applied to images applied in-room through IGRT technologies.

## Materials and methods

A PubMed/MEDLINE and Embase systematic search was performed using definite keywords, according to Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines [31].

The searching strategy included the following keywords: (“Radiomics” [Mesh] OR “Radiomics” [All fields]) AND (“Cone Beam Computed Tomography” [Mesh] OR “Cone Beam Computed Tomography” [All fields]); (“Radiomics” [Mesh] OR “Radiomics” [All fields]) AND (“Magnetic Resonance guided Radiotherapy” [Mesh] OR “Magnetic Resonance guided Radiotherapy” [All fields]); (“Radiomics” [Mesh] OR “Radiomics” [All fields]) AND (“on board Magnetic Resonance Radiotherapy” [Mesh] OR “on board Magnetic Resonance Radiotherapy” [All fields]); (“Artificial Intelligence” [Mesh] OR “Artificial Intelligence” [All fields]) AND (“Cone Beam Computed Tomography” [Mesh] OR “Cone Beam Computed Tomography” [All fields]); (“Artificial Intelligence” [Mesh] OR “Artificial Intelligence” [All fields]) AND (“Magnetic Resonance guided Radiotherapy” [Mesh] OR “Magnetic Resonance guided Radiotherapy” [All fields]); (“Artificial Intelligence” [Mesh] OR “Artificial Intelligence” [All fields]) AND (“on board Magnetic Resonance Radiotherapy” [Mesh] OR “on board Magnetic Resonance Radiotherapy” [All fields]).

Original articles up to 01.11.2022 were selected, and the exclusion criteria were defined as: 1) not original articles (e.g., abstracts, reviews, editorials, book chapters, letters, congress communications or posters); 2) articles that were not in English language; 3) papers not referred to IGRT imaging techniques; 4) papers not presenting results about radiomics and AI applications.

A board composed by two radiation oncologists (AD, AP) selected all articles, an independent validation of three experts in radiomics and AI was also performed (LB, VN, VS).

A final validation of the whole process was performed by other 5 different independent expert radiation oncologists (FDF, ID, RG, CG, GCI).

## Results

A total of 402 studies were obtained using the mentioned search strategy on PubMed/MEDLINE and further 249 articles were obtained on EMBASE.

Following title and abstract analysis, 131 papers were selected according to the previously reported exclusion criteria.

After full-text analysis, 44 papers were discarded according to selection criterion 4, as not referred to radiomics or AI applied to IGRT imaging modalities. After the completion of the selection process, 84 papers were considered eligible for the analysis of the results.

Figure 1 reports the flowchart of the systematic literature search process.

The range of publication year goes from 2011 to 2022 and all the studies included in the analysis resulted to be retrospective.

In the subset of papers regarding radiomics ( $n=23$ ), the feature extraction was performed on on-board MR treatment images in 31% ( $n=7$ ) [9, 11, 14, 32–35] and CBCT in 69% ( $n=16$ ) of the cases [36–51]. The median number of patients involved in the analysis was 30 (range 10–337); the median number of considered radiomics features was 110 (range 2–2317).

Eight studies (34%) analyzed the technical feasibility and reproducibility aspects of radiomics analysis [11, 14, 32–34, 36–44], while the correlation of radiomic features

and treatment response was the focus of fifteen studies (66%) [35, 45–51].

Table 1 summarizes the main characteristics of the analyzed radiomics studies, including aim, conclusions, and corresponding cluster area.

In the subset of papers regarding AI ( $n=61$ ), the analysis was performed on CBCT in the 56% ( $n=34$ ) [52–87] and on MRIgRT treatment images in the 44% ( $n=27$ ) [5, 52, 79, 88–111].


The median number of patients involved in the analysis was 45 (range 1–480).

Thirty studies (49%) analyzed AI in the generation of synthetic imaging [5, 52–70, 75, 79, 88–93, 99], while autosegmentation and autoplanning were investigated in 20 studies (32%) [71–79, 95–106]. Plan quality assurance and dose calculation were the focus of 15 papers (24%) [55, 57–59, 63–65, 67, 69, 70, 80, 81, 94, 107, 108], treatment delivery optimization was investigated in eight studies (12%) [82–86, 90, 109, 110], while response prediction in 2 studies (3%) [87, 111] as summarized in Tables 2 and 3.

## Discussion

The results of this systematic review underline the effort that the radiation oncology community has addressed to apply radiomics and AI modalities on modern IGRT images as a result of the ongoing attempts to provide personalized radiotherapy treatment and workflow optimizations.

**Fig. 1** Flowchart of the systematic literature search process



**Table 1** Articles regarding radomics applied to in-room IGRT images

First author (country/year)	No of patients	Objectives	Cluster area	IGRT modality	No of features	Conclusions
Boldrini L et al. (Italy, 2019) [14]	16	To predict cCR in patients affected by RC undergoing neoadjuvant CRT using 0.35 T MRI-based delta-radomics features	Treatment response prediction	MRgRT	318	0.35 T MRI-based delta-radomics is promising to predict cCR ( $p$ value < 0.001)
Tomaszewski M R et al. (USA, 2021) [32]	26	To predict PFS in patients affected by PDAC undergoing SBRT using 0.35 T MRI-based delta-radomics features	Treatment response prediction	MRgRT	73	0.35 T MRI-based delta-radomics is promising to predict PFS prediction ( $p$ value = 0.005)
Chiloiro G et al. (Italy, 2022) [33]	48	To predict 2yDFS in patients affected by RC undergoing neoadjuvant CRT using 0.35 T MRI-based delta-radomics features	Treatment response prediction	MRgRT	1099	0.35 T MRI-based delta-radomics is adequate to predict DFS (AUC 0.92)
Simpson et al. (USA, 2022) [34]	30	To predict treatment response in patients with PDAC who underwent SBRT using 0.35 T MRI-based delta-radomics	Treatment response prediction	MRgRT	39	0.35 T MRI-based delta-radomics is adequate to predict tumor response (AUC 0.845)
Xue C et al. (China, 2021) [35]	26	To determine repeatability of radomics features between MR-LINAC scans and reproducibility between MRI-simulator and MR-Linac scans	technical feasibility and reproducibility aspects of radomics analysis	MRgRT	1023	A reliable selection of MRgRT features is needed for the validation of radomics studies
van Timmeren J A et al. (the Netherlands, 2019) [36]	337	To predict toxicity and OS and LC in lung cancer patients undergoing CBCT-based RT. Validation of longitudinal methods	Treatment response prediction	CBCT pCT	2317	No validation of clinical parameters for OS and LC
Qin Q et al. (China, 2021) [37]	34	To predict toxicity and PFS in lung cancer patients undergoing CBCT-based SBRT	Treatment response prediction	CBCT	144	CBCT-based radomics resulted to be adequate in predicting PFS (AUC 0.918) and lung injury (AUC 0.952)
Bosetti D G et al. (Switzerland, 2020) [38]	31	To predict risk stratification and biochemical relapse in PC patients undergoing CBCT-based RT	Treatment response prediction	CBCT	31	CBCT-based radomics is adequate to predict selected outcomes (AUC 0.83–0.93)
Shi L et al. (USA, 2020) [39]	23	To predict OS in locally advanced in lung cancer patients undergoing CBCT-based RT	Treatment response prediction	CBCT	658	Early CBCT-based radomics features could be correlated with overall survival in locally advanced lung cancer ( $p$ value < 0.05)

**Table 1** (continued)

First author (country/year)	No of patients	Objectives	Cluster area	IGRT modality	No of features	Conclusions
Morgan H E et al. (USA, 2021) [40]	30	To predict LF in H&N patients undergoing CBCT-based RT	Treatment response prediction	CBCT	30	CBCT-based radomics resulted to be adequate in predicting LF in primary (AUC 0.871) and nodal (AUC 0.91) sites
Du F et al. (China, 2020) [41]	96	To develop a nomogram predicting the risk of RT related pneumonitis in esophageal squamous cell carcinoma	Treatment response prediction	CBCT	851	CBCT radomics provided a model based on early lung CBCT for predicting pneumonitis (AUC 0.836–0.918)
Sellami S et al. (France, 2022) [42]	93	To identify a CBCT radiomic signature predictive of progression in H&N radiotherapy	Treatment response prediction	CBCT	88	The CBCT radomics model showed an early change in features possibly correlating with treatment response
Iliadou V et al. (Greece, 2022) [43]	40	To develop a CBCT radomics-based model to determine tumor volume variations in H&N radiotherapy	Treatment response prediction	CBCT	104	CBCT features analysis led to a high accuracy (0.90 $p < 0.01$ ) in determine CTV variations
Zhang R et al. (China, 2022) [44]	10	To develop a CBCT radomics-based model to determine tumor volume variations in lung radiotherapy	Treatment response prediction	CBCT	1371	CBCT analysis led to the identification of stable radomics features to predict tumor response during RT
van Timmeren J A et al. (the Netherlands, 2017) [45]	90	To determine a selection model for radomics features in lung cancer patients undergoing CBCT-based RT	technical feasibility and reproducibility aspects of radomics analysis	CBCT	116	Combining baseline and longitudinal radomics resulted in a reliable selection model in LC
van Timmeren J A et al. (the Netherlands, 2017) [46]	288	To investigate the interchangeability of pCT and CBCT extracted radiomic features to predict survival in lung cancer patients undergoing CBCT-based RT	technical feasibility and reproducibility aspects of radomics analysis	CBCT pCT	1119	CBCT radomics can provide selected features that are interchangeable when extracted from either planning CT or cone-beam CT images
Delgadillo R et al. (USA, 2021) [47]	20	To determine repeatability of radomics features in PC RT	technical feasibility and reproducibility aspects of radomics analysis	CBCT pCT	42	CBCT radiomic features showed correlation with pCT features also to be used for prognostic models
Bagher-Ebadian H et al. (USA, 2017) [48]	18	To investigate the characteristics of radomics feature in CBCT and pCT images in H&N radiotherapy	technical feasibility and reproducibility aspects of radomics analysis	CBCT pCT	165	CBCT and pCT radomics features showed interchangeability investigating radomics features as possible biomarkers for outcome

**Table 1** (continued)

First author (country/year)	No of patients	Objectives	Cluster area	IGRT modality	No of features	Conclusions
Fave X et al. (USA, 2015)	[49] 10	To determine the feasibility of CBCT-based radionics features analysis in lung cancer radiotherapy	technical feasibility and reproducibility aspects of radionics analysis	CBCT	68	CBCT radionics features were found to be consistent in image protocols with less than 1 cm of tumor motion
Wang H et al. (China, 2021)	[50] 20	To determine the repeatability and reproducibility of CBCT radionics features in H&N and pelvic radiotherapy	technical feasibility and reproducibility aspects of radionics analysis	CBCT	18	CBCT radionics features were found to both repeatable and reproducible even if disease/protocol-specific and correlated to time between scans
Gu J et al. (China, 2018)	[51] 22	To determine reproducibility of MVCT images radionics analysis in lung cancer tomotherapy	technical feasibility and reproducibility aspects of radionics analysis	CBCT	195	MVCT features analysis resulted to be feasible even if motion frequency could affect texture features
Cusumano D et al. (Italy, 2021)	[11] 43	To validate a prediction model for cCR and pCR in patients affected by RC undergoing neoadjuvant CRT using 0.35 T MRI-based delta-radionics features	Treatment response prediction	MRgRT	2	0.35 T MRI-based delta-radionics is adequate to predict cCR and pCR (AUC 0.81)
Cusumano D et al. (Italy, 2021)	[9] 35	To predict LC in patients affected by PDAC undergoing SBRT using 0.35 T MRI-based delta-radionics features	Treatment response prediction	MRgRT	92	0.35 T MRI-based delta-radionics is promising in 1-year local control prediction (AUC = 0.78, $p$ value = 0.005)

**Table 2** Articles regarding AI applied to CBCT IGRT

First author (country/year)	No of patients	Objectives	Cluster area	IGRT modality	Conclusions
Schooley J E et al. (USA, 2022)	[52] 120	To implement an MR-only workflow by synthesizing MVCT from MRI	Synthetic imaging generation	CBCT MRgRT	The study demonstrates the feasibility of using MRI-derived sMVCT in an MR-only treatment planning workflow
Liang X et al. (USA, 2019)	[53] 110	To develop a DL approach to generate sCT images from CBCT in H&N RT	Synthetic imaging generation	CBCT	The study demonstrated the feasibility of sCT generation using generative adversarial networks
Yuan N et al. (China, 2020)	[54] 55	To develop a DL model to enhance CBCT images for adaptive H&N radiotherapy	Synthetic imaging generation	CBCT	The study demonstrated the quantitative and qualitative accuracy of DL generated CBCT images
Irmak S et al. (Austria, 2021)	[55] 41	To develop a DL approach to generate sCT images from CBCT images in H&N RT	Synthetic imaging generation Plan quality assurance and dose calculation	CBCT	The study demonstrated the feasibility of sCT generation using a DL approach with good dose calculation results (gamma pass rates $99.0 \pm 0.4\%$ )
Chen L et al. (USA, 2021)	[56] 143	To develop a DL approach to generate sCT images from CBCT images	Synthetic imaging generation	CBCT	The study demonstrated the effectiveness of sCT generation using a DL approach
Gao L et al. (China, 2021)	[57] 170	To develop attention-guided generative adversarial networks approach to generate sCT images from CBCT	Synthetic imaging generation Plan quality assurance and dose calculation	CBCT	The study demonstrated the feasibility of sCT generation using a DL approach with good dose calculation results (gamma pass rates $91.4 \pm 3.26$ )
Qiu R L J et al. (USA, 2021)	[58] 20	To develop DL to generate sCT images from thoracic SBRT CBCT	Synthetic imaging generation Plan quality assurance and dose calculation	CBCT	The study demonstrated the feasibility of accurate sCT generation using a DL approach
Xue X et al. (China, 2021)	[59] 169	To develop DL approach to generate sCT images from nasopharyngeal treatments CBCT	Synthetic imaging generation Plan quality assurance and dose calculation	CBCT	The study demonstrated the feasibility of sCT generation using a DL approach with good dose calculation results (gamma pass rates $> 95\%$ )
Liu J et al. (China, 2021)	[60] 52	To develop DL approach to generate sCT images from nasopharyngeal treatments CBCT	Synthetic imaging generation Plan quality assurance and dose calculation	CBCT	The study demonstrated the feasibility of sCT generation
Zhang Y et al. (USA, 2021)	[61] 25	To develop DL approach to generate sCT images from H&N and pelvic treatments CBCT	Synthetic imaging generation	CBCT	The study demonstrated the feasibility of sCT generation
Chen L et al. (USA, 2020)	[62] 37	To develop DL approach to generate sCT images from CBCT	Synthetic imaging generation	CBCT	The study demonstrated the feasibility of sCT generation

**Table 2** (continued)

First author (country/year)	No of patients	Objectives	Cluster area	IGRT modality	Conclusions
Uh J et al. (USA, 2021)	[63] 50	To develop DL approach to optimize CBCT quality for adaptive proton therapy in abdominal proton therapy in children and young adults	Synthetic imaging generation Plan quality assurance and dose calculation	CBCT	The study demonstrated the feasibility of CBCT optimization using a DL approach with good dose calculation results (gamma pass rates (98.5 ± 1.9%))
Lemus O MD et al. (USA, 2022)	[64] 17	To develop DL approach to generate sCT images from liver SBRT	Synthetic imaging generation Plan quality assurance and dose calculation	CBCT	The study demonstrated the feasibility of sCT generation using a DL approach with good dose calculation results (gamma pass rates (≥94.11%))
Wu W et al. (China, 2022)	[65] 153	To develop DL approach to generate sCT images from prostate CBCT	Synthetic imaging generation Plan quality assurance and dose calculation	CBCT	The study demonstrated the feasibility of sCT generation using a DL approach. Average structural similarity index measure between sCT and CBCT was higher than pCT (≥94.11%)
Kurosawa T et al. (Japan, 2020)	[66] 36	To improve the image quality of high-speed CBCT using a deep convolutional neural network in prostate cancer	Synthetic imaging generation Plan quality assurance and dose calculation	CBCT	The study developed a model to generate high-speed and high-quality CBCT
Thummerer A (the Netherlands, 2021)	[67] 27	To develop DL approach to generate sCT images from LUNG proton treatments	Synthetic imaging generation Plan quality assurance and dose calculation	CBCT	The study demonstrated the feasibility of sCT generation using a DL approach with good dose calculation results (gamma pass rates (96.8%))
Li Y et al. (China, 2019)	[68] 70	To develop DL approach to generate sCT images from nasopharyngeal treatments CBCT	Synthetic imaging generation Plan quality assurance and dose calculation	CBCT	The study demonstrated the feasibility of accurate sCT generation
Thummerer A (the Netherlands, 2020)	[69] 27	To develop DL approach to generate sCT images from H&N proton treatments	Synthetic imaging generation Plan quality assurance and dose calculation	CBCT	The study demonstrated the feasibility of sCT generation using a DL approach with good dose calculation results (gamma pass rates (96.1%))
Maspero M et al. (the Netherlands, 2020)	[70] 99	To investigate feasibility of applying a single convolutional network for dose calculation based on CBCT for H&N, lung, and breast cancer treatments	Plan quality assurance and dose calculation Synthetic imaging generation	CBCT	The study demonstrated the accuracy of generated sCT also for dose calculation
Sibolt P et al. (Denmark, 2021)	[71] 39	To demonstrate the feasibility of oART in pelvic district with autocontouring and autoplanning in CBCT-based AI solutions	Autosegmentation and Autoplanning	CBCT	The study demonstrated feasibility of oART in pelvic region. Adapted plan resulted to be superior in PTV coverage in 88% of cases
Li R et al. (USA, 2021)	[72] 16	To develop a DL method to predict tumor shrinking and generate CBCT-based autocontours	Autosegmentation and Autoplanning	CBCT	The study demonstrated a high prediction accuracy of target autocontours DL method (DSC 0.78–0.82)

**Table 2** (continued)

First author (country/year)	No of patients	Objectives	Cluster area	IGRT modality	Conclusions
Han X et al. (USA, 2021)	[73] 40	To develop a DL method for CBCT-based autocontours in pancreatic radiotherapy	Autosegmentation and Autoplaning	CBCT	The study demonstrated a high prediction accuracy of target autocontours DL method for OARs (DSC 0.714 and 0.858 for bowel and stomach/duodenum)
Jiang J et al. (USA, 2021)	[74] 69	To develop a DL CBCT lung tumor segmentation method	Autosegmentation and Autoplaning	CBCT	The study demonstrated a high prediction accuracy of target autocontours
Alam S R et al. (USA, 2021)	[75] 191	To develop a method for esophagus autosegmentation in lung radiotherapy to prevent toxicity	Autosegmentation and Autoplaning Synthetic imaging generation	CBCT pCT	The study demonstrated a high accuracy of AS model for CBCTs-based RT (DSC 0.74–0.81)
Liang X et al. (USA, 2022)	[76] 251	To develop a DL method for CBCT-based contours propagation from pCT to CBCT in prostate radiotherapy	Autosegmentation and Autoplaning	CBCT	The study demonstrated a high prediction accuracy of DL contours propagation from pCT to CBCT method (DSC 0.85±0.04)
Schreirer J et al. (Finland, 2020)	[77] 11	To develop a DL method for CBCT-based autocontours in prostate radiotherapy	Autosegmentation and Autoplaning	CBCT	The study demonstrated a high prediction accuracy of autocontours DL propagation from pCT to CBCT method for OARs (DSC 0.701 and 0.932)
Åström L M et al. (Denmark, 2022)	[78] 16	To evaluate the feasibility and dosimetric impact of CBCT-guided oART of urinary bladder cancer	Autosegmentation and Autoplaning	CBCT	The study demonstrated feasibility of oART in pelvic region. Adapted plan resulted to be superior in PTV coverage in 98% of cases
Wang C et al. (USA, 2020)	[79] 11	To develop a method for esophagus spatial changes evaluation in lung radiotherapy to prevent toxicity	Autosegmentation and Autoplaning Synthetic imaging generation	CBCT MRgRT	The study developed a model with high prediction of esophagus volume (>0.98)
Lalond A et al. (USA, 2020)	[80] 48	To develop a DL method to perform CBCT correction for adaptive proton radiotherapy in H&N	Plan quality assurance and dose calculation	CBCT	The study developed an accurate DL method for CBCT correction with dose calculation (gamma pass rates 98.89%)
Harms P et al. (USA, 2020)	[81] 23	To develop a DL method to perform online dose calculation from CBCT-based proton radiotherapy in H&N	Plan quality assurance and dose calculation	CBCT	The study developed an accurate DL method for CBCT-guided adaptive planning (MAE 0.06±0.01, gamma passing rate 94%)
Luximon D C et al. (USA, 2022)	[82] 480	To develop a neural network to optimize and correct vertebral body misalignments in thoracic and abdominal radiotherapy	Delivery optimization	CBCT	The study developed a neural model with high accuracy (AUC>99%) in identifying and correcting setup misalignments

**Table 2** (continued)

First author (country/year)	No of patients	Objectives	Cluster area	IGRT modality	Conclusions
Liang X et al. (China, 2020)	[83] 6	To develop a DL model PTV localization on CBCT in prostate radiotherapy	Delivery optimization	CBCT	The study demonstrated the development of DL-based PTV localization technique showing strong correlations ( $>0.94$ ) in the couch shifts between model prediction and the reference
Fu Y et al. (USA, 2021)	[84] 50	To develop a DL method to register and deform MRI images to delineate clinical volumes on CBCT in prostate treatments	Delivery optimization	CBCT	The study demonstrated an accurate registration for CBCT contouring (DSC $0.93 \pm 0.01$ )
Zhang S et al. (China, 2022)	[85] 45	To develop a CBCT radionics-based model to determine ITV in lung radiotherapy	Delivery optimization	CBCT	The study showed a DL model to predict ITV variation in lung SBRT with good accuracy (DSC $0.83 \pm 0.18$ )
Kai Y et al. (Japan, 2020)	[86] 20	To develop and test a ML model to predict target shifts in CBCT prostate radiotherapy	Delivery optimization	CBCT	The study demonstrated the accuracy of the model to predict the target shifts (mean absolute residual errors were $\leq 1.04$ mm)
Dohopolski M et al. (USA, 2022)	[87] 271	To develop a ML- and DL-based method to early identify cluster of H&N patients who will need feeding tube supplementation	Treatment response prediction	CBCT	The study developed a clinical and image-based model with good prediction accuracy (AUC 0.75)

**Table 3** Articles regarding AI applied to MRgRT/IGRT

First author (country/year)	No of patients	Objectives	Cluster area	IGRT modality	Conclusions
Cusumano D et al. (Italy,2020) [5]	120	To develop a DL approach to generate sCT images from low field MR images in pelvis and abdomen	Synthetic imaging generation	MRgRT	The study demonstrated the feasibility of sCT generation using a DL approach for low field MR images in pelvis and abdomen, also showing a reliable calculation of IMRT plans in MRgRT
Schooley J E et al. (USA, 2022) [52]	120	To implement an MR-only workflow by synthesizing MVCT from MRI	Synthetic imaging generation	CBCT and MRgRT	The study demonstrates the feasibility of using MRI-derived sMVCT in an MR-only treatment planning workflow
Sibolt P et al. (Denmark, 2021) [71]	39	To demonstrate the feasibility of oART in pelvic district with autocontouring and autoplanning in CBCT-based AI solutions	Autosegmentation and Autoplanning	CBCT	The study demonstrated feasibility of oART in pelvic region. Adapted plan resulted to be superior in PTV coverage in 88% of cases
Wang C et al. (USA, 2020) [79]	11	To develop a method for esophagus spatial changes evaluation in lung radiotherapy to prevent toxicity	Autosegmentation and Autoplanning	CBCT MRgRT	The study developed a model with high prediction of esophagus volume (> 0.98)
Lalond A et al. (USA, 2020) [80]	48	To develop a DL method to perform CBCT correction for adaptive proton radiotherapy in H&N	Synthetic imaging generation Plan quality assurance and dose calculation	CBCT	The study developed an accurate DL method for CBCT correction with dose calculation (gamma pass rates 98–89%)
Harms P et al. (USA, 2020) [81]	23	To develop a DL method to perform online dose calculation from CBCT-based proton radiotherapy in H&N	Plan quality assurance and dose calculation	CBCT	The study developed an accurate DL method for CBCT-guided adaptive planning (MAE 0.06 ± 0.01, gamma passing rate 94%)
Cusumano D et al. (Italy,2020) [88]	26	To evaluate the dose calculation accuracy of using bulk sCT in presence of 0.35 T magnetic field in abdominal and pelvic adaptive RT	Synthetic imaging generation	MRgRT	The study demonstrates the reliability of generating synthetic CT using bulk REI assignment to address the inter-fraction variability in MR-guided radiotherapy
Lenkowicz J et al. (Italy, 2022) [89]	60	To generate synthetic Computed Tomography (sCT) from 0.35 Tesla MRI of the thorax	Synthetic imaging generation	MRgRT	The study demonstrates the image and dose accuracy of generating synthetic CT for in lung MRgRT
Terpstra M A et al. (the Netherlands, 2020) [90]	135	To develop and test a DL imaging reconstruction and motion estimation model for MRgRT	Synthetic imaging generation Delivery optimization	MRgRT	The study demonstrated the accuracy (root-mean-square error ± 1 mm) of DL-based image reconstruction and motion estimation for online adaptive MRgRT with minimal latency

**Table 3** (continued)

First author (country/year)	No of patients	Objectives	Cluster area	IGRT modality	Conclusions
Chun J et al. (Korea, 2021)	[91]	To develop and test a DL high-resolution imaging reconstruction model for MRgRT	Synthetic imaging generation	MRgRT	The study demonstrated the generation of DL-based high-resolution imaging for online adaptive MRgRT with minimal latency
Olberg S et al. (USA, 2021)	[92]	To develop a DL approach to generate sCT images from low field MR images in abdomen	Synthetic imaging generation	MRgRT	The study demonstrated the feasibility of sCT generation using a DL approach for low field MR images in abdomen, with limitations for subset of patients with notable differences in intestinal gas
Olberg S et al. (USA, 2019)	[93]	To develop a DL approach to generate sCT images from low field MR images in breast	Synthetic imaging generation	MRgRT	The study demonstrated the feasibility of sCT generation using a DL approach for low field MR images in breast and abdomen, also showing a reliable dose calculation ( $\geq 98\%$ passing rate for dose distribution)
Allan Thomas M et al. (USA, 2020)	[94]	To develop and test ML dose predicting model for adaptive MRgRT plan quality evaluation	Plan quality assurance and dose calculation	MRgRT	The study developed and tested a ML prediction model for 3D dose distribution in abdominal adaptive MRgRT (dose prediction error $0.1 \pm 3.4$ Gy)
Chen X et al. (China, 2022)	[95]	To develop autosegmentation (AS) framework for online delineation of prostate cancer using MRgRT	Autosegmentation and Autoplanning	MRgRT	The study developed an accurate segmentation model (DSC 0.79 to 0.93 for CTV) to shorten online adaptive MRgRT workflow
Tong N et al. (China, 2019)	[96]	To develop AS framework for H&N MRgRT	Autosegmentation and Autoplanning	MRgRT	The study tested a segmentation model for H&N delineation (DSC 0.6–0.916)
Friedrich F et al. (Germany, 2021)	[97]	To develop AS framework for online delineation in lung	Autosegmentation and Autoplanning	MRgRT	The study developed a segmentation model for stomach delineation (DSC $> 0.83$ )
Kawula M et al. (Germany, 2022)	[98]	To train convolutional neural networks (CNNs) for automatic segmentation of OARs and CTV for prostate cancer patients treated with 0.35 T MR-Linac	Autosegmentation and Autoplanning	MRgRT	The study demonstrated a high accuracy of AS model for OARs (DSC 0.88–0.93) and CTV (DSC 0.72–0.88)

**Table 3** (continued)

First author (country/year)	No of patients	Objectives	Cluster area	IGRT modality	Conclusions	
Chun J et al. (Korea, 2022)	[99]	60	To train AS framework in replanning CTs for traditional ART. To test AS in MRgRT and sCT generation	Autosegmentation and Autoplanning Synthetic imaging generation	pCT MRgRT	The study demonstrated a high accuracy of AS model for sCT-based RT (DSC 0.95). The developed model resulted in mean absolute error improvement for AS and sCT for MRgRT compared to conventional model
Liang F et al. (USA, 2018)	[100]	4	To develop autosegmentation (AS) framework for online delineation of abdominal district using MRgRT	Autosegmentation and Autoplanning	MRgRT	The study developed an accurate segmentation model (DSC above 0.86)
Eppenhof K A J et al. (the Netherlands, 2020)	[101]	5	To develop AS framework for online delineation of prostate cancer using MRgRT	Autosegmentation and Autoplanning	MRgRT	The study developed an accurate segmentation model (DSC 0.86 ± 0.05)
Künzel L A et al. (Germany, 2021)	[102]	1	To develop AS and autoplanning for prostate cancer MRgRT	Autosegmentation and Autoplanning	MRgRT	The study demonstrated the feasibility of an autonomous, un-supervised data preparation and plan generation for prostate MRgRT
Hague C et al. (UK, 2021)	[103]	30	To develop AS model for parotid and submandibular glands in H&N radiotherapy, comparing a CT-based to MR-based model	Autosegmentation and Autoplanning	MRgRT pCT	The study demonstrates better performance of the AS MR-based mode (DSC ≥ 0.80)
Chen Y et al. (USA, 2020)	[104]	102	To develop AS framework for online delineation of abdominal district in MRgRT	Autosegmentation and Autoplanning	MRgRT	The study developed an accurate segmentation model (DSC 0.80–0.96)
Huang L et al. (China 2021)	[105]	25	To develop AS framework for online delineation of stomach in MRgRT	Autosegmentation and Autoplanning	MRgRT	The study developed a segmentation model for stomach delineation (DSC 0.77)
Luximon D C et al. (USA, 2022)	[106]	116	To develop AS framework for online delineation of stomach in MRgRT	Autosegmentation and Autoplanning	MRgRT	The study developed a segmentation model for stomach delineation (Dice 0.91 ± 0.02)
Kajikawa T et al. (Japan, 2020)	[107]	50	To develop a DL-based dose distribution conversion approach for the correction of the influence of a magnetic field for online MRgRT in prostate cancer	Plan quality assurance and dose calculation	MRgRT	The study developed and tested a DL dose correction model for MRgRT (gamma indexes 94.95% ± 4.69%)
Li M et al. (Australia, 2020)	[108]	1	To develop a neural network to correct the geometric distortions in MR images in pelvic MRgRT	Plan quality assurance and dose calculation	MRgRT	The study demonstrated the feasibility of deep neural network for field deviations in the 1 T MRI-Linac system to optimize real-time MRgRT

**Table 3** (continued)

First author (country/year)	No of patients	Objectives	Cluster area	IGRT modality	Conclusions
Cerviño L I et al. (USA, 2011) [109]	5	To develop and test a template matching (TM) and an artificial neural network (ANN) tumor-tracking system in lung MRgRT	Delivery optimization	MRgRT	The study demonstrated a high accuracy in template matching (TM) algorithm in combination with surrogate tracking using the diaphragm
Liu L et al. (USA, 2022) [110]	7	To develop a DL tumor-tracking system in MRgRT	Delivery optimization	MRgRT	The study demonstrated an accuracy in DL GTV tracking with $0.4 \pm 0.3$ mm and $0.5 \pm 0.4$ mm median distance for cine and radial acquisitions
Gao Y et al. (USA, 2021) [111]	30	To predict soft tissue sarcoma response using a novel deep-learning prediction framework in MRgRT	Treatment response prediction	MRgRT	The study demonstrated the accuracy of DL in predicting pathologic response from longitudinal DWI (97.1% and patient-based prediction)

AI Artificial Intelligence, AS Auto Segmentation, AUC area under the curve, CBCT Cone Beam Computed Tomography, CCR Clinical Complete Response, CRT Chemo-Radiotherapy, DFS Disease Free Survival, DL Deep Learning, H&N Head and Neck, ITV Internal Target Volume, LC Local Control, MVT Mega Voltage Computed Tomography, MRgRT Magnetic Resonance-guided Radiation Therapy, MRI Magnetic Resonance Imaging, oART online Adaptive Radiation Therapy, OS Overall Survival, PC Prostate Cancer, pCT planning CT planning, sCT synthetic CT Tomography, PDAC Pancreatic Ductal AdenoCarcinoma, PFS Progression Free Survival, PTV Planning Target Volume, SBRT Stereotactic Body Radiation Therapy

Conventional radiomics is based on the extraction of quantitative image features from a region of interest (ROI) with the subsequent creation of a model correlated with clinical endpoints. In this context, delta-radiomics analyzes the temporal variation of radiomic features to assess sensitivity during treatment of the tumor understood as a heterogeneous entity [8].

Specific biomarkers of treatment response can be identified in this context. One of these is the early regression index (ERITCP) whose validity has been demonstrated, for example, in locally advanced rectal cancer. This index models the radiobiologic behavior of the tumor by considering its volumetric regression from simulated treatment ( $V_{pre}$ ) to mid-treatment ( $V_{mid}$ ) [112]. Promising results have been shown in the analysis of features in MRI-guided treatments of rectal and pancreatic cancer, evidence have shown that delta-radiomics could predict cCR and pCR (AUC 0.81) in rectal cancer and LC (AUC 0.79) in pancreatic cancer [9, 11].

Several settings have been investigated by the authors, varying from the possibility to correlate treatment data to clinical outcomes or exploiting innovative optimization approaches.

In the largest number of analyzed studies, radiomics and AI aim to lead to optimized stratification of patients with the goal of better defining their risk category and tailoring treatment models accordingly. The input information derived from IGRT image analysis also allows to develop response prediction models for response to treatments.

The availability of such models can radically modify the foreseen therapeutic strategies, proposing online plan re-optimization or dose modifications.

Several experiences also correlated data extracted from in-room IGRT-derived images to the onset of treatment-related toxicities in different sites, suggesting the need for improvement strategies in terms of dose delivery accuracy, made possible by the most modern delivery technologies.

Cone Beam CT-based radiomics analysis showed good results in terms of treatment outcomes prediction, with a major interest in toxicity prediction in head and neck and thoracic malignancies [37, 40, 41]. Interestingly, some very recent studies have proposed the application of radiomics-based predictive models on in-room MRI images, showing an overall high level of prediction of tumor response in different sites also in this innovative treatment IGRT framework [11, 32, 33].

The development of AI-based systems and radiomics that can predict treatment outcomes may further support the development of innovative adaptive radiotherapy approaches, suggesting the need for dose adaptation to poor-responder patients [113]. This approach represents the backbone of a first prospective interventional clinical trial that uses image derived biomarkers to stratify

patients undergoing neoadjuvant chemoradiotherapy for locally advanced rectal cancer on a 0.35 T MR Linac in risk classes and guiding dose escalation protocols, introducing a brand new concept of clinical trials in RT [114].

The applications of AI techniques also play an emerging role in optimizing the different phases of radiation treatment by increasing safety and standardization. One of the most optimizable areas is reducing the time required for workflow. This aspect is even more crucial in MRI-guided treatments, which have been shown to be time-consuming processes in different experiences [115–117]. Autosegmentation and autoplanning models speed up the planning steps while providing a high standard of quality and consistent performances, less prone to interobserver variability.

Reducing treatment times through AI applications, particularly in online adaptive treatments, also has the advantage of increasing patient's compliance to treatment, offering more tolerable treatment sessions.

Besides the clinical advantages, applying AI-based quality assurance (QA) tools to the different phases of radiation treatment planning and delivery is another central area of investigation and research. In this context, there are growing experiences in developing methods for creating synthetic imaging from in-room IGRT images to optimize dose calculation on the patient's daily anatomy and disclose unprecedented approaches for online adaptation.

In conclusion, the evidence available in the literature is based on small retrospective datasets but describes a significant impact of radiomics and AI applied to modern in-room IGRT methods in all the phases of radiation treatment.

Further confirmation about the potentialities of these tools will come from prospective studies of correlation with clinical outcomes and gold standard treatment workflows and strategies.

**Acknowledgements** The Authors thank the Scientific Committee and Board of the AIRO for the critical revision and final approval of the manuscript (Nr. 7/2023).

**Author contributions** Conception and design: L.B., V.S., A.D'. Data Collection, analysis, and interpretation of data: A.D', A.P. Analysis Validation: L.B., F.DeF., I.D., R.G., C.G., G.C.I., V.N., V.S. Manuscript Writing: A.D', A.P., L.B. The Final Manuscript Approval: all authors.

**Funding** All authors received no specific funding for this work.

## Declarations

**Conflict of interest** All authors declare no conflicts of interests.

**Ethical approval and consent to participate** No Ethical approval was needed due to the design of the study.

**Consent for publication** No consent to publication was needed due to the design of the study.

## References

1. Ramesh AN, Kambhampati C, Monson JRT, Drew PJ (2004) Artificial intelligence in medicine. *Ann R Coll Surg Engl* 86:334–338. <https://doi.org/10.1308/147870804290>
2. Vandewinckele L, Claessens M, Dinkla A et al (2020) Overview of artificial intelligence-based applications in radiotherapy: recommendations for implementation and quality assurance. *Radiother Oncol* 153:55–66. <https://doi.org/10.1016/j.radonc.2020.09.008>
3. Huynh E, Hosny A, Guthier C et al (2020) Artificial intelligence in radiation oncology. *Nat Rev Clin Oncol* 17:771–781. <https://doi.org/10.1038/s41571-020-0417-8>
4. Cesario A, D’Oria M, Calvani R et al (2021) The role of artificial intelligence in managing multimorbidity and cancer. *J Pers Med* 11:314. <https://doi.org/10.3390/jpm11040314>
5. Cusumano D, Lenkowicz J, Votta C et al (2020) A deep learning approach to generate synthetic CT in low field MR-guided adaptive radiotherapy for abdominal and pelvic cases. *Radiother Oncol* 153:205–212. <https://doi.org/10.1016/j.radonc.2020.10.018>
6. Gambacorta MA, Valentini C, Dinapoli N et al (2013) Clinical validation of atlas-based auto-segmentation of pelvic volumes and normal tissue in rectal tumors using auto-segmentation computed system. *Acta Oncol* 52:1676–1681. <https://doi.org/10.3109/0284186X.2012.754989>
7. Fionda B, Boldrini L, D’Aviero A et al (2020) Artificial intelligence (AI) and interventional radiotherapy (brachytherapy): state of art and future perspectives. *J Contemp Brachyther* 12:497–500. <https://doi.org/10.5114/jcb.2020.100384>
8. Nardone V, Reginelli A, Grassi R et al (2021) Delta radiomics: a systematic review. *Radiol Med* 126:1571–1583. <https://doi.org/10.1007/s11547-021-01436-7>
9. Cusumano D, Boldrini L, Yadav P et al (2021) Delta radiomics analysis for local control prediction in pancreatic cancer patients treated using magnetic resonance guided radiotherapy. *Diagnostics* 11:72. <https://doi.org/10.3390/diagnostics11010072>
10. Casà C, Piras A, D’Aviero A et al (2022) The impact of radiomics in diagnosis and staging of pancreatic cancer. *Ther Adv Gastrointest Endosc* 15:26317745221081596. <https://doi.org/10.1177/26317745221081596>
11. Cusumano D, Boldrini L, Yadav P et al (2021) Delta radiomics for rectal cancer response prediction using low field magnetic resonance guided radiotherapy: an external validation. *Phys Med* 84:186–191. <https://doi.org/10.1016/j.ejmp.2021.03.038>
12. Alongi P, Stefano A, Comelli A et al (2021) Radiomics analysis of 18F-Choline PET/CT in the prediction of disease outcome in high-risk prostate cancer: an explorative study on machine learning feature classification in 94 patients. *Eur Radiol* 31:4595–4605. <https://doi.org/10.1007/s00330-020-07617-8>
13. Chiloiro G, Rodriguez-Carnero P, Lenkowicz J et al (2020) Delta radiomics can predict distant metastasis in locally advanced rectal cancer: the challenge to personalize the cure. *Front Oncol* 10:595012. <https://doi.org/10.3389/fonc.2020.595012>
14. Boldrini L, Cusumano D, Chiloiro G et al (2019) Delta radiomics for rectal cancer response prediction with hybrid 0.35 T magnetic resonance-guided radiotherapy (MRgRT): a hypothesis-generating study for an innovative personalized medicine approach. *Radiol Med* 124:145–153. <https://doi.org/10.1007/s11547-018-0951-y>
15. Lambin P, Rios-Velazquez E, Leijenaar R et al (2012) Radiomics: extracting more information from medical images using advanced feature analysis. *Eur J Cancer* 48:441–446. <https://doi.org/10.1016/j.ejca.2011.11.036>
16. Gardin I, Grégoire V, Gibon D et al (2019) Radiomics: principles and radiotherapy applications. *Crit Rev Oncol Hematol* 138:44–50. <https://doi.org/10.1016/j.critrevonc.2019.03.015>
17. Luh JY, Albuquerque KV, Cheng C et al (2020) ACR-ASTRO practice parameter for image-guided radiation therapy (IGRT). *Am J Clin Oncol* 43:459–468. <https://doi.org/10.1097/COC.00000000000000697>
18. Gillan C, Giuliani M, Harnett N et al (2016) Image guided radiation therapy: unlocking the future through knowledge translation. *Int J Radiat Oncol Biol Phys* 96:248–250. <https://doi.org/10.1016/j.ijrobp.2016.05.028>
19. Sharma M, Nano TF, Akkati M et al (2022) A systematic review and meta-analysis of liver tumor position variability during SBRT using various motion management and IGRT strategies. *Radiother Oncol* 166:195–202. <https://doi.org/10.1016/j.radonc.2021.11.022>
20. Lee J, Liu S-H, Lin J-B et al (2018) Image-guided study of inter-fraction and intra-fraction set-up variability and margins in reverse semi-decubitus breast radiotherapy. *Radiat Oncol* 13:254. <https://doi.org/10.1186/s13014-018-1200-1>
21. Corradini S, Alongi F, Andratschke N et al (2019) MR-guidance in clinical reality: current treatment challenges and future perspectives. *Radiat Oncol* 14:92. <https://doi.org/10.1186/s13014-019-1308-y>
22. Boldrini L, Cusumano D, Cellini F et al (2019) Online adaptive magnetic resonance guided radiotherapy for pancreatic cancer: state of the art, pearls and pitfalls. *Radiat Oncol* 14:71. <https://doi.org/10.1186/s13014-019-1275-3>
23. Zhang Y, Liang Y, Ding J et al (2022) A prior knowledge-guided, deep learning-based semiautomatic segmentation for complex anatomy on magnetic resonance imaging. *Int J Radiat Oncol Biol Phys* 114:349–359. <https://doi.org/10.1016/j.ijrobp.2022.05.039>
24. D’Aviero A, Re A, Catucci F et al (2022) Clinical validation of a deep-learning segmentation software in head and neck: an early analysis in a Developing Radiation Oncology Center. *Int J Environ Res Public Health* 19:9057. <https://doi.org/10.3390/ijerph19159057>
25. Brunt AM, Haviland JS, Wheatley DA et al (2020) Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. *The Lancet* 395:1613–1626. [https://doi.org/10.1016/S0140-6736\(20\)30932-6](https://doi.org/10.1016/S0140-6736(20)30932-6)
26. Piras A, Menna S, D’Aviero A et al (2021) New fractionations in breast cancer: a dosimetric study of 3D-CRT versus VMAT. *J Med Radiat Sci*. <https://doi.org/10.1002/jmrs.530>
27. Ling DC, Vargo JA, Beriwal S (2020) Breast, prostate, and rectal cancer: Should 5–5–5 be a new standard of care? *Int J Radiat Oncol Biol Phys* 108:390–393. <https://doi.org/10.1016/j.ijrobp.2020.06.049>
28. Piras A, Boldrini L, Menna S et al (2021) Hypofractionated radiotherapy in head and neck cancer elderly patients: a feasibility and safety systematic review for the clinician. *Front Oncol* 11:761393. <https://doi.org/10.3389/fonc.2021.761393>
29. Massaccesi M, Boldrini L, Piras A et al (2020) Spatially fractionated radiotherapy (SFRT) targeting the hypoxic tumor segment for the intentional induction of non-targeted effects: an in silico study to exploit a new treatment paradigm. *Tech Innov Patient Support Radiat Oncol* 14:11–14. <https://doi.org/10.1016/j.tipsro.2020.02.003>
30. Piras A, Venuti V, D’Aviero A et al (2022) Covid-19 and radiotherapy: a systematic review after 2 years of pandemic. *Clin Transl Imaging* 66:1–20. <https://doi.org/10.1007/s40336-022-00513-9>

31. Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 372:n71. <https://doi.org/10.1136/bmj.n71>
32. Tomaszewski MR, Latifi K, Boyer E et al (2021) Delta radiomics analysis of magnetic resonance guided radiotherapy imaging data can enable treatment response prediction in pancreatic cancer. *Radiat Oncol* 16:237. <https://doi.org/10.1186/s13014-021-01957-5>
33. Chiloiro G, Boldrini L, Preziosi F et al (2022) A predictive model of 2yDFS during MR-guided RT neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. *Front Oncol* 12:831712. <https://doi.org/10.3389/fonc.2022.831712>
34. Simpson G, Jin W, Spieler B et al (2022) Predictive value of delta-radiomics texture features in 0.35 Tesla magnetic resonance setup images acquired during stereotactic ablative radiotherapy of pancreatic cancer. *Front Oncol* 12:807725. <https://doi.org/10.3389/fonc.2022.807725>
35. Xue C, Yuan J, Poon DM et al (2021) Reliability of MRI radiomics features in MR-guided radiotherapy for prostate cancer: repeatability, reproducibility, and within-subject agreement. *Med Phys* 48:6976–6986. <https://doi.org/10.1002/mp.15232>
36. van Timmeren JE, van Elmpt W, Leijenaar RTH et al (2019) Longitudinal radiomics of cone-beam CT images from non-small cell lung cancer patients: evaluation of the added prognostic value for overall survival and locoregional recurrence. *Radioter Oncol* 136:78–85. <https://doi.org/10.1016/j.radonc.2019.03.032>
37. Qin Q, Shi A, Zhang R et al (2020) Cone-beam CT radiomics features might improve the prediction of lung toxicity after SBRT in stage I NSCLC patients. *Thorac Cancer* 11:964–972. <https://doi.org/10.1111/1759-7714.13349>
38. Bossetti DG, Ruinelli L, Piliero MA et al (2020) Cone-beam computed tomography-based radiomics in prostate cancer: a mono-institutional study. *Strahlenther Onkol* 196:943–951. <https://doi.org/10.1007/s00066-020-01677-x>
39. Shi L, Rong Y, Daly M et al (2020) Cone-beam computed tomography-based delta-radiomics for early response assessment in radiotherapy for locally advanced lung cancer. *Phys Med Biol* 65:015009. <https://doi.org/10.1088/1361-6560/ab3247>
40. Morgan HE, Wang K, Dohopolski M et al (2021) Exploratory ensemble interpretable model for predicting local failure in head and neck cancer: the additive benefit of CT and intra-treatment cone-beam computed tomography features. *Quant Imaging Med Surg* 11:4781–4796. <https://doi.org/10.21037/qims-21-274>
41. Du F, Tang N, Cui Y et al (2020) A novel nomogram model based on cone-beam CT radiomics analysis technology for predicting radiation pneumonitis in esophageal cancer patients undergoing radiotherapy. *Front Oncol* 10:596013. <https://doi.org/10.3389/fonc.2020.596013>
42. Sellami S, Bourbonne V, Hatt M et al (2022) Predicting response to radiotherapy of head and neck squamous cell carcinoma using radiomics from cone-beam CT images. *Acta Oncol* 61:73–80. <https://doi.org/10.1080/0284186X.2021.1983207>
43. Iliadou V, Kakkos I, Karaikos P et al (2022) Early prediction of planning adaptation requirement indication due to volumetric alterations in head and neck cancer radiotherapy: a machine learning approach. *Cancers* 14:3573. <https://doi.org/10.3390/cancers14153573>
44. Zhang R, Cai Z, Luo Y et al (2022) Preliminary exploration of response course of radiotherapy for stage III non-small cell lung cancer based on longitudinal CT radiomics features. *Eur J Radiol Open* 9:100391. <https://doi.org/10.1016/j.ejro.2021.100391>
45. van Timmeren JE, Leijenaar RTH, van Elmpt W et al (2017) Feature selection methodology for longitudinal cone-beam CT radiomics. *Acta Oncol* 56:1537–1543. <https://doi.org/10.1080/0284186X.2017.1350285>
46. van Timmeren JE, Leijenaar RTH, van Elmpt W et al (2017) Survival prediction of non-small cell lung cancer patients using radiomics analyses of cone-beam CT images. *Radioter Oncol* 123:363–369. <https://doi.org/10.1016/j.radonc.2017.04.016>
47. Delgadillo R, Spieler BO, Ford JC et al (2021) Repeatability of CBCT radiomic features and their correlation with CT radiomic features for prostate cancer. *Med Phys* 48:2386–2399. <https://doi.org/10.1002/mp.14787>
48. Bagher-Ebadian H, Siddiqui F, Liu C et al (2017) On the impact of smoothing and noise on robustness of CT and CBCT radiomics features for patients with head and neck cancers. *Med Phys* 44:1755–1770. <https://doi.org/10.1002/mp.12188>
49. Fave X, Mackin D, Yang J et al (2015) Can radiomics features be reproducibly measured from CBCT images for patients with non-small cell lung cancer? *Med Phys* 42:6784–6797. <https://doi.org/10.1111/1.4934826>
50. Wang H, Zhou Y, Wang X et al (2021) Reproducibility and repeatability of CBCT-derived radiomics features. *Front Oncol* 11:773512. <https://doi.org/10.3389/fonc.2021.773512>
51. Gu J, Zhu J, Qiu Q et al (2018) The feasibility study of Megavoltage Computed Tomographic (MVCT) image for texture feature analysis. *Front Oncol* 8:586. <https://doi.org/10.3389/fonc.2018.00586>
52. Scholey JE, Rajagopal A, Vasquez EG et al (2022) Generation of synthetic megavoltage CT for MRI-only radiotherapy treatment planning using a 3D deep convolutional neural network. *Med Phys* 49:6622–6634. <https://doi.org/10.1002/mp.15876>
53. Liang X, Chen L, Nguyen D et al (2019) Generating synthesized computed tomography (CT) from cone-beam computed tomography (CBCT) using CycleGAN for adaptive radiation therapy. *Phys Med Biol* 64:125002. <https://doi.org/10.1088/1361-6560/ab22f9>
54. Yuan N, Dyer B, Rao S et al (2020) Convolutional neural network enhancement of fast-scan low-dose cone-beam CT images for head and neck radiotherapy. *Phys Med Biol* 65:035003. <https://doi.org/10.1088/1361-6560/ab6240>
55. Irmak S, Zimmermann L, Georg D et al (2021) Cone beam CT based validation of neural network generated synthetic CTs for radiotherapy in the head region. *Med Phys* 48:4560–4571. <https://doi.org/10.1002/mp.14987>
56. Chen L, Liang X, Shen C et al (2021) Synthetic CT generation from CBCT images via unsupervised deep learning. *Phys Med Biol*. <https://doi.org/10.1088/1361-6560/ac01b6>
57. Gao L, Xie K, Wu X et al (2021) Generating synthetic CT from low-dose cone-beam CT by using generative adversarial networks for adaptive radiotherapy. *Radiat Oncol* 16:202. <https://doi.org/10.1186/s13014-021-01928-w>
58. Qiu RLJ, Lei Y, Shelton J et al (2021) Deep learning-based thoracic CBCT correction with histogram matching. *Biomed Phys Eng Express*. <https://doi.org/10.1088/2057-1976/ac3055>
59. Xue X, Ding Y, Shi J et al (2021) Cone Beam CT (CBCT) based synthetic CT generation using deep learning methods for dose calculation of nasopharyngeal carcinoma radiotherapy. *Technol Cancer Res Treat* 20:15330338211062416. <https://doi.org/10.1177/15330338211062415>
60. Liu J, Yan H, Cheng H et al (2021) CBCT-based synthetic CT generation using generative adversarial networks with disentangled representation. *Quant Imaging Med Surg* 11:4820–4834. <https://doi.org/10.21037/qims-20-1056>
61. Zhang Y, Yue N, Su M-Y et al (2021) Improving CBCT quality to CT level using deep learning with generative adversarial network. *Med Phys* 48:2816–2826. <https://doi.org/10.1002/mp.14624>
62. Chen L, Liang X, Shen C et al (2020) Synthetic CT generation from CBCT images via deep learning. *Med Phys* 47:1115–1125. <https://doi.org/10.1002/mp.13978>

63. Uh J, Wang C, Acharya S et al (2021) Training a deep neural network coping with diversities in abdominal and pelvic images of children and young adults for CBCT-based adaptive proton therapy. *Radiother Oncol* 160:250–258. <https://doi.org/10.1016/j.radonc.2021.05.006>
64. Lemus OMD, Wang Y-F, Li F et al (2022) Dosimetric assessment of patient dose calculation on a deep learning-based synthesized computed tomography image for adaptive radiotherapy. *J Appl Clin Med Phys* 23:e13595. <https://doi.org/10.1002/acm2.13595>
65. Wu W, Qu J, Cai J, Yang R (2022) Multiresolution residual deep neural network for improving pelvic CBCT image quality. *Med Phys* 49:1522–1534. <https://doi.org/10.1002/mp.15460>
66. Kurosawa T, Nishio T, Moriya S et al (2020) Feasibility of image quality improvement for high-speed CBCT imaging using deep convolutional neural network for image-guided radiotherapy in prostate cancer. *Phys Med* 80:84–91. <https://doi.org/10.1016/j.ejmp.2020.10.012>
67. Thummerer A, Seller Oriá C, Zaffino P et al (2021) Clinical suitability of deep learning based synthetic CTs for adaptive proton therapy of lung cancer. *Med Phys* 48:7673–7684. <https://doi.org/10.1002/mp.15333>
68. Li Y, Zhu J, Liu Z et al (2019) A preliminary study of using a deep convolution neural network to generate synthesized CT images based on CBCT for adaptive radiotherapy of nasopharyngeal carcinoma. *Phys Med Biol* 64:145010. <https://doi.org/10.1088/1361-6560/ab2770>
69. Thummerer A, de Jong BA, Zaffino P et al (2020) Comparison of the suitability of CBCT- and MR-based synthetic CTs for daily adaptive proton therapy in head and neck patients. *Phys Med Biol* 65:235036. <https://doi.org/10.1088/1361-6560/abb1d6>
70. Maspero M, Houweling AC, Savenije MHF et al (2020) A single neural network for cone-beam computed tomography-based radiotherapy of head-and-neck, lung and breast cancer. *Phys Imaging Radiat Oncol* 14:24–31. <https://doi.org/10.1016/j.phro.2020.04.002>
71. Sibolt P, Andersson LM, Calmels L et al (2021) Clinical implementation of artificial intelligence-driven cone-beam computed tomography-guided online adaptive radiotherapy in the pelvic region. *Phys Imaging Radiat Oncol* 17:1–7. <https://doi.org/10.1016/j.phro.2020.12.004>
72. Li R, Roy A, Bice N et al (2021) Managing tumor changes during radiotherapy using a deep learning model. *Med Phys* 48:5152–5164. <https://doi.org/10.1002/mp.14925>
73. Han X, Hong J, Reyngold M et al (2021) Deep-learning-based image registration and automatic segmentation of organs-at-risk in cone-beam CT scans from high-dose radiation treatment of pancreatic cancer. *Med Phys* 48:3084–3095. <https://doi.org/10.1002/mp.14906>
74. Jiang J, Riyahi Alam S, Chen I et al (2021) Deep cross-modality (MR-CT) educated distillation learning for cone beam CT lung tumor segmentation. *Med Phys* 48:3702–3713. <https://doi.org/10.1002/mp.14902>
75. Alam SR, Li T, Zhang P et al (2021) Generalizable cone beam CT esophagus segmentation using physics-based data augmentation. *Phys Med Biol* 66:065008. <https://doi.org/10.1088/1361-6560/abe2eb>
76. Liang X, Bibault J-E, Leroy T et al (2021) Automated contour propagation of the prostate from pCT to CBCT images via deep unsupervised learning. *Med Phys* 48:1764–1770. <https://doi.org/10.1002/mp.14755>
77. Schreier J, Genghi A, Laaksonen H et al (2020) Clinical evaluation of a full-image deep segmentation algorithm for the male pelvis on cone-beam CT and CT. *Radiother Oncol* 145:1–6. <https://doi.org/10.1016/j.radonc.2019.11.021>
78. Åström LM, Behrens CP, Calmels L et al (2022) Online adaptive radiotherapy of urinary bladder cancer with full re-optimization to the anatomy of the day: Initial experience and dosimetric benefits. *Radiother Oncol* 171:37–42. <https://doi.org/10.1016/j.radonc.2022.03.014>
79. Wang C, Alam RS, Zhang S et al (2020) Predicting spatial esophageal changes in a multimodal longitudinal imaging study via a convolutional recurrent neural network. *Phys Med Biol* 65:235027. <https://doi.org/10.1088/1361-6560/abb1d9>
80. Lalonde A, Winey B, Verburg J et al (2020) Evaluation of CBCT scatter correction using deep convolutional neural networks for head and neck adaptive proton therapy. *Phys Med Biol*. <https://doi.org/10.1088/1361-6560/ab9fcb>
81. Harms J, Lei Y, Wang T et al (2020) Cone-beam CT-derived relative stopping power map generation via deep learning for proton radiotherapy. *Med Phys* 47:4416–4427. <https://doi.org/10.1002/mp.14347>
82. Luximon DC, Ritter T, Fields E et al (2022) Development and interinstitutional validation of an automatic vertebral-body misalignment error detector for cone-beam CT-guided radiotherapy. *Med Phys* 49:6410–6423. <https://doi.org/10.1002/mp.15927>
83. Liang X, Zhao W, Hristov DH et al (2020) A deep learning framework for prostate localization in cone beam CT-guided radiotherapy. *Med Phys* 47:4233–4240. <https://doi.org/10.1002/mp.14355>
84. Fu Y, Wang T, Lei Y et al (2021) Deformable MR-CBCT prostate registration using biomechanically constrained deep learning networks. *Med Phys* 48:253–263. <https://doi.org/10.1002/mp.14584>
85. Zhang S, Lv B, Zheng X et al (2022) Dosimetric study of deep learning-guided ITV prediction in cone-beam CT for lung stereotactic body radiotherapy. *Front Public Health* 10:860135. <https://doi.org/10.3389/fpubh.2022.860135>
86. Kai Y, Arimura H, Ninomiya K et al (2020) Semi-automated prediction approach of target shifts using machine learning with anatomical features between planning and pretreatment CT images in prostate radiotherapy. *J Radiat Res* 61:285–297. <https://doi.org/10.1093/jrr/rzz105>
87. Dohopolski M, Wang K, Morgan H et al (2022) Use of deep learning to predict the need for aggressive nutritional supplementation during head and neck radiotherapy. *Radiother Oncol* 171:129–138. <https://doi.org/10.1016/j.radonc.2022.04.016>
88. Cusumano D, Placidi L, Teodoli S et al (2020) On the accuracy of bulk synthetic CT for MR-guided online adaptive radiotherapy. *Radiol Med* 125:157–164. <https://doi.org/10.1007/s11547-019-01090-0>
89. Lenkowicz J, Votta C, Nardini M et al (2022) A deep learning approach to generate synthetic CT in low field MR-guided radiotherapy for lung cases. *Radiother Oncol* 176:31–38. <https://doi.org/10.1016/j.radonc.2022.08.028>
90. Terpstra ML, Maspero M, d'Agata F et al (2020) Deep learning-based image reconstruction and motion estimation from undersampled radial k-space for real-time MRI-guided radiotherapy. *Phys Med Biol* 65:155015. <https://doi.org/10.1088/1361-6560/ab9358>
91. Chun J, Zhang H, Gach HM et al (2019) MRI super-resolution reconstruction for MRI-guided adaptive radiotherapy using cascaded deep learning: In the presence of limited training data and unknown translation model. *Med Phys* 46:4148–4164. <https://doi.org/10.1002/mp.13717>
92. Olberg S, Chun J, Su Choi B et al (2021) Abdominal synthetic CT reconstruction with intensity projection prior for MRI-only adaptive radiotherapy. *Phys Med Biol*. <https://doi.org/10.1088/1361-6560/ac279e>
93. Olberg S, Zhang H, Kennedy WR et al (2019) Synthetic CT reconstruction using a deep spatial pyramid convolutional framework for MR-only breast radiotherapy. *Med Phys* 46:4135–4147. <https://doi.org/10.1002/mp.13716>

94. Thomas MA, Fu Y, Yang D (2020) Development and evaluation of machine learning models for voxel dose predictions in online adaptive magnetic resonance guided radiation therapy. *J Appl Clin Med Phys* 21:60–69. <https://doi.org/10.1002/acm2.12884>
95. Chen X, Ma X, Yan X et al (2022) Personalized auto-segmentation for magnetic resonance imaging-guided adaptive radiotherapy of prostate cancer. *Med Phys* 49:4971–4979. <https://doi.org/10.1002/mp.15793>
96. Tong N, Gou S, Yang S et al (2019) Shape constrained fully convolutional densenet with adversarial training for multi-organ segmentation on head and neck CT and low field MR images. *Med Phys* 46:2669–2682. <https://doi.org/10.1002/mp.13553>
97. Friedrich F, Hörner-Rieber J, Renkamp CK et al (2021) Stability of conventional and machine learning-based tumor auto-segmentation techniques using undersampled dynamic radial bSSFP acquisitions on a 0.35 T hybrid MR-linac system. *Med Phys* 48:587–596. <https://doi.org/10.1002/mp.14659>
98. Kawula M, Hadi I, Nierer L et al (2022) Patient-specific transfer learning for auto-segmentation in adaptive 0.35 T MRgRT of prostate cancer: a bi-centric evaluation. *Med Phys*. <https://doi.org/10.1002/mp.16056>
99. Chun J, Park JC, Olberg S et al (2022) Intentional deep over-fit learning (IDOL): a novel deep learning strategy for adaptive radiation therapy. *Med Phys* 49:488–496. <https://doi.org/10.1002/mp.15352>
100. Liang F, Qian P, Su K-H et al (2018) Abdominal, multi-organ, auto-contouring method for online adaptive magnetic resonance guided radiotherapy: An intelligent, multi-level fusion approach. *Artif Intell Med* 90:34–41. <https://doi.org/10.1016/j.artmed.2018.07.001>
101. Eppenhof K, a. J, Maspero M, Savenije MHF, et al (2020) Fast contour propagation for MR-guided prostate radiotherapy using convolutional neural networks. *Med Phys* 47:1238–1248. <https://doi.org/10.1002/mp.13994>
102. Künzel LA, Nachbar M, Hagmüller M et al (2021) First experience of autonomous, un-supervised treatment planning integrated in adaptive MR-guided radiotherapy and delivered to a patient with prostate cancer. *Radiother Oncol* 159:197–201. <https://doi.org/10.1016/j.radonc.2021.03.032>
103. Hague C, McPartlin A, Lee LW et al (2021) An evaluation of MR based deep learning auto-contouring for planning head and neck radiotherapy. *Radiother Oncol* 158:112–117. <https://doi.org/10.1016/j.radonc.2021.02.018>
104. Chen Y, Ruan D, Xiao J et al (2020) Fully automated multiorgan segmentation in abdominal magnetic resonance imaging with deep neural networks. *Med Phys* 47:4971–4982. <https://doi.org/10.1002/mp.14429>
105. Huang L, Li M, Gou S et al (2021) Automated segmentation method for low field 3D stomach MRI using transferred learning image enhancement network. *Biomed Res Int* 2021:6679603. <https://doi.org/10.1155/2021/6679603>
106. Luximon DC, Abdulkadir Y, Chow PE et al (2022) Machine-assisted interpolation algorithm for semi-automated segmentation of highly deformable organs. *Med Phys* 49:41–51. <https://doi.org/10.1002/mp.15351>
107. Kajikawa T, Kadoya N, Tanaka S et al (2020) Dose distribution correction for the influence of magnetic field using a deep convolutional neural network for online MR-guided adaptive radiotherapy. *Phys Med* 80:186–192. <https://doi.org/10.1016/j.ejmp.2020.11.002>
108. Li M, Shan S, Chandra SS et al (2020) Fast geometric distortion correction using a deep neural network: Implementation for the 1 Tesla MRI-Linac system. *Med Phys* 47:4303–4315. <https://doi.org/10.1002/mp.14382>
109. Cerviño LI, Du J, Jiang SB (2011) MRI-guided tumor tracking in lung cancer radiotherapy. *Phys Med Biol* 56:3773. <https://doi.org/10.1088/0031-9155/56/13/003>
110. Liu L, Shen L, Johansson A et al (2022) Real time volumetric MRI for 3D motion tracking via geometry-informed deep learning. *Med Phys* 49:6110–6119. <https://doi.org/10.1002/mp.15822>
111. Gao Y, Ghodrati V, Kalbasi A et al (2021) Prediction of soft tissue sarcoma response to radiotherapy using longitudinal diffusion MRI and a deep neural network with generative adversarial network-based data augmentation. *Med Phys* 48:3262–3372. <https://doi.org/10.1002/mp.14897>
112. Fiorino C, Gumina C, Passoni P et al (2018) A TCP-based early regression index predicts the pathological response in neoadjuvant radio-chemotherapy of rectal cancer. *Radiother Oncol* 128:564–568. <https://doi.org/10.1016/j.radonc.2018.06.019>
113. Salvestrini V, Greco C, Guerini AE et al (2022) The role of feature-based radiomics for predicting response and radiation injury after stereotactic radiation therapy for brain metastases: a critical review by the Young Group of the Italian Association of Radiotherapy and Clinical Oncology (yAIRO). *Transl Oncol* 15:101–275. <https://doi.org/10.1016/j.tranon.2021.101275>
114. Chiloiro G, Cusumano D, Boldrini L et al (2022) THUNDER 2: THeragnostic Utilities for Neoplastic DisEases of the Rectum by MRI guided radiotherapy. *BMC Cancer* 22:67. <https://doi.org/10.1186/s12885-021-09158-9>
115. Tang B, Liu M, Wang B et al (2022) Improving the clinical workflow of a MR-Linac by dosimetric evaluation of synthetic CT. *Front Oncol* 12:66
116. Votta C, Cusumano D, Boldrini L et al (2021) Delivery of online adaptive magnetic resonance guided radiotherapy based on isodose boundaries. *Phys Imaging Radiat Oncol* 18:78–81. <https://doi.org/10.1016/j.phro.2021.05.005>
117. Placidi L, Cusumano D, Boldrini L et al (2020) Quantitative analysis of MRI-guided radiotherapy treatment process time for tumor real-time gating efficiency. *J Appl Clin Med Phys* 21:70–79. <https://doi.org/10.1002/acm2.13030>

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.